Skip to content

Anti-osteoporosis Medication Monitoring and Management Service

Anti-osteoporosis Medication Monitoring and Management Service

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02194647
Enrollment
500
Registered
2014-07-18
Start date
2014-07-01
Completion date
2026-07-01
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture, Osteoporosis

Keywords

Osteoporosis, Medication Monitoring, Education, Adherence, Management

Brief summary

BACKGROUND: One-year adherence to oral anti-osteoporosis medication (AOMs) was only about 30%. In recent years, efforts have been made to change the delivery of these medications from oral form to injection form every, 3, 6 or 12 months to increase adherence. However, both patients and providers are sometimes confused about the multiple choices. Also, patients may receive extra medications if providers did not keep tract of their previous AOM uses or patients may changes providers. There were urgent needs to provide AOM monitoring and management services to improve cares. OBJECTIVES: To establish a anti-osteoporosis medication management service at National Taiwan University Hospital and its BeiHu Branch. METHODS: Participating physicians will select those eligible for services and refer to study coordinators. Study coordinators will conduct baseline assessments on osteoporosis/fracture risks, record medical conditions, AOMs, provide educations on osteoporosis, fracture, sarcopenia, fall, medications, nutrition, and exercise. They also arrange return clinic visit, telephone reminder and follow up for patients, and communicate with providers on regular bases. the investigators plan to enroll 500 patients with 18-month follow up for each.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>=50 and one of the below * Newly prescribed with AOMs * Recent change of AOMs * Poor adherence to AOMs * Participating physicians feel that the service will benefit the patient in overall osteoporosis and medication managements.

Exclusion criteria

* Life expectancy less than 2 years or can't be assessed for communication problems * patient in our fracture liaison service or other medication clinical trials

Design outcomes

Primary

MeasureTime frameDescription
medication adherence18 monthsMedication adherence will be assessed at 4, 8, 12, 18 months after enrollments. Final results will be reported at 18 month. If the patient changes medication, all AOMs adherence will be combined. Specific formula is as below: for oral medications, adherence is defined as # medication taken/ #medication prescribed within past 3 months for injection medications, adherence is defined as # of injection/ # of due injection since baseline or last follow up phone call. Statistics: Simple counts of adherence % among all participants.

Countries

Taiwan

Contacts

PRINCIPAL_INVESTIGATORDing-Cheng Chan, MD, PhD

National Taiwan University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026